… In conclusion, immune therapy has no proven role in adjuvant therapy of RCC. Future
autologous vaccine trials will need to be conservatively reported with the intention-to-treat analysis …

… aspect of adjuvant therapy is to select patients who are at increased risk of recurrence to
benefit from adjuvant therapy and to spare low-risk patients from the adverse effects of adjuvant …

… adjuvant setting. There have been a number of phase III clinical trials reported recently
exploring the use of targeted agents as adjuvant therapy, … trials investigating adjuvant therapy in …

… therapies with immunotherapy, neoadjuvant approaches and patient selection will be key to
determining optimal adjuvant therapy … weakness of the five adjuvant antiangiogenic TKI trials…

… This work provides an overview of current and ongoing trials of adjuvant (postoperative)
therapy for localized renal cell carcinoma. Currently, the gold standard in this disease setting is …

… adjuvant setting or being considered for future adjuvant trials. Here, we discuss the past,
present, and future of adjuvant therapy … high risk for relapse following definitive surgical therapy. …

… Adjuvant radiotherapy is associated with a marked decrease in local recurrences and a …
In this study, patients who received adjuvant radiation therapy had improved outcomes …

… to adjuvant setting. In this review, we examine current evidence for adjuvant therapies in RCC,
… clinical trials and suggest future directions in the search for an effective adjuvant therapy. …

… of patients who received surgery, adjuvant RT, and adjuvant CRT remained stable (Figure
1)… received adjuvant therapy. Most patients who received postoperative therapy had adjuvant …

… role of surgical staging, adjuvant therapy, and cytoreduction in uterine clear cell carcinoma
(UCCC). … Vaginal brachytherapy may be adequate adjuvant therapy for stages I and II UCCC …